featured
Belzutifan vs Everolimus for Advanced Renal Cell Carcinoma
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
The New England Journal of Medicine
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Belzutifan versus Everolimus for Advanced Renal-Cell Carcinoma
N. Engl. J. Med 2024 Aug 22;391(8)710-721, TK Choueiri, T Powles, K Peltola, G de Velasco, M Burotto, C Suarez, P Ghatalia, R Iacovelli, ET Lam, E Verzoni, M Gümüş, WM Stadler, C Kollmannsberger, B Melichar, B Venugopal, M Gross-Goupil, A Poprach, M De Santis, FA Schutz, SH Park, DA Nosov, C Porta, JL Lee, X Garcia-Del-Muro, E Biscaldi, R Manneh Kopp, M Oya, L He, A Wang, RF Perini, D Vickery, L Albiges, B RiniFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Renal Cell Carcinoma Center of Excellence
Visit our Renal Cell Carcinoma Center of Excellence for additional, in-depth coverage.